American Journal of Cardiology
Volume 102, Issue 10 , Pages 1341-1347 , 15 November 2008

Comparison of Treatment of Severe High-Density Lipoprotein Cholesterol Deficiency in Men With Daily Atorvastatin (20 mg) Versus Fenofibrate (200 mg) Versus Extended-Release Niacin (2 g)

Received 2 April 2008 ,Revised 13 July 2008 ,Accepted 13 July 2008.

References 

  1. National Institutes of Health. Lipid Research Clinics Population Studies Databook, Volume 1 (NIH Publication 80-1527). In: Washington, DC: Department of Health and Human Services, Public Health Service; 1980;p. 28–81
  2. Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr Opin Cardiol. 2006;21:329–335
  3. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  4. McPherson R, Frohlich J, Fodor G, Genest J Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913–927
  5. Krimbou L, Hassan HH, Blain S, Rashid S, Denis M, Marcil M, et al. Biogenesis and speciation of nascent apoA-I–containing particles in various cell lines. J Lipid Res. 2005;46:1668–1677
  6. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J. Characterization of oligomeric human ATP binding cassette transporter A1 (Potential implication for determining the structure of nascent HDL particles). J Biol Chem. 2004;279:41529–41536
  7. Alrasadi K, Ruel I, Marcil M, Genest J. Functional mutations in the ABCA1 gene in subjects of French Canadian descent with HDL deficiency. Atherosclerosis. 2006;188:281–291
  8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease (The Framingham Study). Am J Med. 1977;62:707–714
  9. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk (The PROCAM experience and pathophysiological implications for reverse cholesterol transport). Atherosclerosis. 1996;124(suppl):S11–S20
  10. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 2000;153:263–272
  11. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case–control study. Lancet. 2004;364:937–952
  12. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  13. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983;52(suppl):9B–12B
  14. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug (A 50 anniversary review). J Intern Med. 2005;258:94–114
  15. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  16. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405–418
  17. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17:631–636
  18. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849–1861
  19. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  20. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia (Safety of treatment, changes in risk factors, and incidence of coronary heart disease). N Engl J Med. 1987;317:1237–1245
  21. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group). N Engl J Med. 1999;341:410–418
  22. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423
  23. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  24. Van der Steeg WA, Holme I, Boekholdt M, Lytken Larsen M, Lindhal C, Stroes ESG, et al HDL cholesterol, HDL particle size and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol. 2008;51:634–642
  25. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama. 2003;290:2292–2300
  26. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–1682
  27. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol. 2007;99:681–685
  28. Barter PJ. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler Thromb Vasc Biol. 2005;25:1305–1306
  29. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199–2211

 Financial support for this trial was obtained from the research funds of Dr. Genest and Canadian Institutes of Health Research funds MOP 15042 and MOP 62834 at the McGill University Health Center Research Institute, Montréal, Québec, Canada.

PII: S0002-9149(08)01184-3

doi: 10.1016/j.amjcard.2008.07.010

American Journal of Cardiology
Volume 102, Issue 10 , Pages 1341-1347 , 15 November 2008

Article Tools

* Image Usage & Resolution